Publications

Export 188 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R
Raziky, M. E., W. El-Akel, M. A. Soliman, S. El Kafrawy, M. Abdel-Hamid, M. K. Mostafa, M. Sjogren, T. Strickland, and G. Esmat. "Sustained virological responders to interferon therapy for chronic hepatitis C Genotype 4: is there a possibility of relapse?" LIVER INTERNATIONAL 26 (2006): 4. Abstract
n/a
S
Saad, Yasmin, Olfat Shaker, Yasser Nassar, Lama Ahmad, Mohamed Said, and Gamal Esmat. "A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infection." Gut and liver 8, no. 6 (2014): 655-61. Abstract

BACKGROUND/AIMS: A polymorphism in the microsomal triglyceride transfer protein (MTP) is associated with hepatic fibrosis, and carriers showed higher levels of steatosis, higher levels of hepatitis C virus (HCV) RNA and advanced fibrosis. The aim of this study was to study MTP expression pattern in HCV patients and impact of the MTP polymorphism on the response to antiviral therapy.

METHODS: One hundred consecutive naive HCV genotype 4 patients were recruited to receive antiviral therapy, and 40 control subjects were also recruited. Demographic, laboratory, and histopathology data were collected. DNA was isolated, and the samples were subjected to polymerase chain reaction analysis and genotyping for MTP by restriction fragment length polymorphism analysis.

RESULTS: Patients and controls were age- and sex-matched (male/female, 56/44, age, 39.2±7.8 years for patients with HCV; male/female, 18/22, age, 38.1±8.1 years for controls). MTP single nucleotide polymorphisms (SNPs) (GG, GT, TT) and alleles (G, T) in the patients versus the controls were 70%, 21%, 9% & 80.5%, 19.5% versus 10%, 87.5%, 2.5% & 53.8%, 46.3%, respectively (p=0.0001). The sustained viral response (SVR) of the patients was 60%. SNPs in MTP genotypes (GG, GT, and TT) and alleles (G and T) in the responders and nonresponders were 71.7%, 25%, 3.3% & 84.2%, 15.8% versus 67.5%, 15%, 17.5% & 75%, 25% (p=0.038 and p=0.109, respectively). A multivariate analysis showed that the GT genotype was an independent predictor of SVR (area under the curve 90% and p=0.0001).

CONCLUSIONS: MTP could be a new predictor for SVR to antiviral therapy in patients with HCV genotype 4 infection.

Said, M., G. Esmat, M. El-Shazly, A. Yousry, N. El-Garem, S. Megawer, W. Doss, A. Omar, H. El-Karaksy, M. Basiony et al. "Availability of donors for living donor liver transplantation (LDLT) in area endemic for HCV and schistosomiasis." LIVER INTERNATIONAL 26 (2006): 96. Abstract
n/a
Said, Mohamed, Ayman Yosry, Gamal Esmat, Magdy El-Serafy, Ashraf Omar, Waheed Doss, Adel Hosny, Yaser Hatata, Ebrahem Marawan, Refat Refat Kamel et al. "OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION FOR INCIDENTALLY FOUND HEPATOCELLULAR CARCINOMA." TRANSPLANT INTERNATIONAL 22 (2009): 198. Abstract
n/a
Shaker, Olfat, Heba Bassiony, Maissa El Raziky, Samer S. El-Kamary, Gamal Esmat, Akmal M. El-Ghor, and Mona M. Mohamed. "Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4." MEDIATORS OF INFLAMMATION (2013). Abstract
n/a
Shehab, H., I. Elattar, T. Elbaz, M. Mohey, and G. Esmat. "CUFA algorithm: assessment of liver fibrosis using routine laboratory data." Journal of viral hepatitis 21, no. 12 (2014): 956-64. Abstract

Staging of liver fibrosis is an integral part of the management of HCV. Liver biopsy is hampered by its invasiveness and possibility of sampling error. Current noninvasive methods are disadvantaged by their cost and complexity. In this study, we aimed at developing a noninvasive method for the staging of liver fibrosis based only on routine laboratory tests and clinical data. Basic clinical and laboratory data and liver biopsies were collected from 994 patients presenting for the evaluation of HCV. Logistic regression was used to create a model predictive of fibrosis stages. A sequential test was then developed by combining our new model with APRI. In the training set (497) a model was created by logistic regression for the prediction of significant fibrosis (≥F2), it included platelets, AST and age (PLASA). The areas under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 0.753, 66.8, 71.4, 69.8, 68.4, respectively, while in the validation set (497), they were 0.777, 66.7, 72.8, 68.6 and 71, respectively. These were the best performance indicators when compared to APRI, FIB-4, King's score, platelets, fibrosis index, age-platelet index and Lok index in the same set of patients. A sequential test was then developed including APRI followed by PLASA [Cairo University Fibrosis Assessment (CUFA) algorithm], this allowed saving 20% and 34% of liver biopsies for patients being tested for significant fibrosis and cirrhosis, respectively. In conclusion, the CUFA algorithms at no cost allow saving a significant proportion of patients from performing a liver biopsy or a more complex costly test. These algorithms could be used as the first step in the assessment of liver fibrosis before embarking on the more costly advanced serum markers, Fibroscan or liver biopsy.

Shereen Ahmed El Sobky, Radwa Yehia Mekky· Nada El‑Ekiaby·, Noha Mousaad Elemam· Rana Ahmed Youness· Mohammad El‑Sayed, Mohammed Tarif Hamza, and Gamal Esmat· Ahmed Ihab Abdelaziz. "Epigallocatechin gallate (EGCG) and miR‑548m reduce HCV entry through repression of CD81 receptor in HCV cell models." Archives of Virology 164, no. 6 (2019): 1587-1595 .
Shiha, Gamal, Shiv Kumar Sarin, Alaa Eldin Ibrahim, Masao Omata, Ashish Kumar, Laurentius A. Lesmana, Nancy Leung, Nurdan Tozun, Saeed Hamid, Wasim Jafri et al. "Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)." HEPATOLOGY INTERNATIONAL 3 (2009): 323-333. Abstract
n/a
Shouman, SI, M. K. Mohamed, G. Esmat, M. Attalla, H. Mansour, C. Rekacewicz, R. Rafaat, N. Sharaf, M. El Hosseiny, M. El Daly et al. "Pegylated interfon for treatment of acute hepatitis C in Egypt (ANRS 1213 trial)." JOURNAL OF HEPATOLOGY 42 (2005): 221. Abstract
n/a
Sievert, William, Ibrahim Altraif, Homie A. Razavi, Ayman Abdo, Ezzat Ali Ahmed, Ahmed AlOmair, Deepak Amarapurkar, Chien-Hung Chen, Xiaoguang Dou, Hisham El Khayat et al. "A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt." LIVER INTERNATIONAL 31 (2011): 61-80. Abstract
n/a
Strickland, GT, H. Elhefni, T. Salman, I. Waked, M. Abdel-Hamid, NNH Mikhail, G. Esmat, and A. Fix. "Role of hepatitis C infection in chronic liver disease in Egypt." AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 67 (2002): 436-442. Abstract
n/a
T
Tabll, Ashraf A., Samy B. Khalil, Reern M. EI-Shenawy, Gamal Esmat, Amr Helmy, Abdel Fattah Attallah, and Mostafa K. Ei-Awadyl. "Establishment of hybrid cell lines producing monoclonal antibodies to a synthetic peptide from the E1 region of the hepatitis C virus." JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY 29 (2008): 91-104. Abstract
n/a
Tayel, Sara S., Amal A. Helmy, Rasha Ahmed, Gamal Esmat, Nabila Hamdi, and Ahmed Ihab Abdelaziz. "Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus." ARCHIVES OF VIROLOGY 158 (2013): 1755-1764. Abstract
n/a
U
Umar, Muhammed, Aamir G. Khan, Zaigham Abbas, Sanjeev Arora, Naqvi Asifabbas, Andre Elewaut, Gamal Esmat, Graham Foster, Michael Fried, Khean-L Goh et al. "World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013." Journal of clinical gastroenterology 48, no. 3 (2014): 204-17. Abstract
n/a
V
Vignier, N., G. Esmat, A. Elsharkawy, M. Hassany, P. Bonnard, E. Delarocque-Astagneau, M. Said, R. Raafat, M. El-Hoseiny, A. Fontanet et al. "Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt." JOURNAL OF VIRAL HEPATITIS 18 (2011): E358-E365. Abstract
n/a
W
WAHAB, MFA, and G. Esmat. "THE VALUE OF ULTRASONOGRAPHY IN ASSESSMENT OF PORTAL-HYPERTENSION IN HEPATOSPLENIC SCHISTOSOMIASIS." MEMORIAS DO INSTITUTO OSWALDO CRUZ 87 (1992): 143-147. Abstract
n/a
Waked, Imam, Waheed Doss, Manal Hamdy El-Sayed, Chris Estes, Homie Razavi, Gamal Shiha, Ayman Yosry, and Gamal Esmat. "The current and future disease burden of chronic hepatitis C virus infection in Egypt." Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology 15, no. 2 (2014): 45-52. Abstract
n/a
Waly, A., H. M. El Tayebi, K. A. Hosny, G. Esmat, and A. I. Abdelaziz. "HYPERMETHYLATION OF THE microRNA LET-7A-3 GENE REPRESSES THE PRIMARY AND MATURE LET-7A-3 WITH AN INVERSE CORRELATION TO IGF-II mRNA IN HCV-INDUCED HEPATOCELLULAR CARCINOMA." JOURNAL OF HEPATOLOGY 58 (2013): S448-S449. Abstract
n/a
Wedemeyer, H., A. S. Duberg, M. Buti, W. M. Rosenberg, S. Frankova, G. Esmat, N. Örmeci, H. Van Vlierberghe, M. Gschwantler, U. Akarca et al. "Strategies to manage hepatitis C virus (HCV) disease burden." Journal of viral hepatitis 21 Suppl 1 (2014): 60-89. Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Wiersma, S. T., B. McMahon, J. M. Pawlotsky, C. L. Thio, M. Thursz, S. G. Lim, P. Ocama, G. Esmat, M. Mendy, D. Bell et al. "Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus (vol 31, pg 755, 2011)." LIVER INTERNATIONAL 32 (2012): 174. Abstract
n/a
Y
Yosry, Ayman, Rabab F. Omar, Mohamed Ezz Al Arab, Hanan Abdel-Hafez, Mohamed Gohar, and Gamal Esmat. "Transient Elastography Can Predict the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C." HEPATOLOGY 56 (2012): 844A. Abstract
n/a
Yosry, Ayman, Mohamed Said, Gamal Esmat, Magdy Al-Serafy, Ashraf Omar, Wahid Doss, Dalia Omran, Yasmin Saad, Sanna Kamel, Akram Abdel-Bary et al. "HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt." EXPERIMENTAL AND CLINICAL TRANSPLANTATION 10 (2012): 136-140. Abstract
n/a
Yosry, A., W. Doss, A. Abdel-Bary, G. Esmat, M. El-Serafy, E. Omar, A. El-Tawil, A. Ghaly, A. Hosny, S. Rifaat et al. "Hepatitis C virus genotype 4 recurrence in Egyptian living donor liver transplant recipients." LIVER TRANSPLANTATION 11 (2005): C19. Abstract
n/a
Yosry, Ayman, Mahasen Abdel-Rahman, Gamal Esmat, Magdy El-Serafy, Ashraf Omar, Waheed Doss, Nagla Zayed, Mohamed Said, Tamer Ismail, Adel Hosny et al. "Recurrence of Hepatitis C Virus (Genotype 4) Infection After Living-Donor Liver Transplant in Egyptian Patients." EXPERIMENTAL AND CLINICAL TRANSPLANTATION 7 (2009): 157-163. Abstract
n/a